Literature DB >> 17502044

New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma.

David J Abraham1, Beate Eckes, Vineeth Rajkumar, Thomas Krieg.   

Abstract

The concept of mesenchymal fibroblasts has evolved over the past two decades from a relatively inert structural cell type to a dynamic, pluripotent cell lineage controlling normal connective tissue formation, homeostasis, and repair and as principle players in pathogenic scarring and fibrosis. In wound healing and tissue repair, fibroblasts provide proinflammatory signals and synthesize interstitial collagens, fibronectins, and other matrix components to repair the damaged tissue. Fibroblasts can differentiate into the myofibroblast, a specialized contractile cell type responsible for wound closure, tissue contraction, and scarring. This article reviews our current understanding of the origins of mesenchymal cells and their role in excessive scarring and fibrogenesis and in the systemic fibrotic disease scleroderma.

Entities:  

Mesh:

Year:  2007        PMID: 17502044     DOI: 10.1007/s11926-007-0008-z

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  60 in total

Review 1.  Myofibroblasts and mechano-regulation of connective tissue remodelling.

Authors:  James J Tomasek; Giulio Gabbiani; Boris Hinz; Christine Chaponnier; Robert A Brown
Journal:  Nat Rev Mol Cell Biol       Date:  2002-05       Impact factor: 94.444

Review 2.  Endothelin and endothelin receptor antagonists in systemic rheumatic disease.

Authors:  Maureen D Mayes
Journal:  Arthritis Rheum       Date:  2003-05

Review 3.  Endothelial-pericyte interactions in angiogenesis.

Authors:  Holger Gerhardt; Christer Betsholtz
Journal:  Cell Tissue Res       Date:  2003-07-22       Impact factor: 5.249

4.  IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice.

Authors:  Randle M Gallucci; Eric G Lee; James J Tomasek
Journal:  J Invest Dermatol       Date:  2006-03       Impact factor: 8.551

Review 5.  Mechanical tension and integrin alpha 2 beta 1 regulate fibroblast functions.

Authors:  Beate Eckes; Manon C Zweers; Zhi Gang Zhang; Ralf Hallinger; Cornelia Mauch; Monique Aumailley; Thomas Krieg
Journal:  J Investig Dermatol Symp Proc       Date:  2006-09

6.  Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis.

Authors:  O Distler; T Pap; O Kowal-Bielecka; R Meyringer; S Guiducci; M Landthaler; J Schölmerich; B A Michel; R E Gay; M Matucci-Cerinic; S Gay; U Müller-Ladner
Journal:  Arthritis Rheum       Date:  2001-11

7.  Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease.

Authors:  Yunliang Chen; Xu Shi-Wen; Jonathan van Beek; Laura Kennedy; Marilyn McLeod; Elisabetta A Renzoni; George Bou-Gharios; Sarah Wilcox-Adelman; Paul F Goetinck; Mark Eastwood; Carol M Black; David J Abraham; Andrew Leask
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

8.  Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse.

Authors:  Voon H Ong; Lowri A Evans; Xu Shiwen; Ivan B Fisher; Vineeth Rajkumar; David J Abraham; Carol M Black; Christopher P Denton
Journal:  Arthritis Rheum       Date:  2003-07

Review 9.  Biology of the scleroderma fibroblast.

Authors:  D Strehlow; J H Korn
Journal:  Curr Opin Rheumatol       Date:  1998-11       Impact factor: 5.006

10.  Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds.

Authors:  Howard Y Chang; Julie B Sneddon; Ash A Alizadeh; Ruchira Sood; Rob B West; Kelli Montgomery; Jen-Tsan Chi; Matt van de Rijn; David Botstein; Patrick O Brown
Journal:  PLoS Biol       Date:  2004-01-13       Impact factor: 8.029

View more
  70 in total

Review 1.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

2.  The differential regulation of cell motile activity through matrix stiffness and porosity in three dimensional collagen matrices.

Authors:  Miguel Miron-Mendoza; Joachim Seemann; Frederick Grinnell
Journal:  Biomaterials       Date:  2010-09       Impact factor: 12.479

3.  [Expression of calponin-1 and its pathogenic role in systemic sclerosis].

Authors:  Han Zhao; Kai Yang; Qingmei Liu; Jinghan Hu; Wenyu Wu; Jiucun Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-03-30

Review 4.  Fibroblasts and the ground they walk on.

Authors:  Daniel J Tschumperlin
Journal:  Physiology (Bethesda)       Date:  2013-11

5.  Isoform-specific effects of transforming growth factor β on endothelial-to-mesenchymal transition.

Authors:  Harika Sabbineni; Arti Verma; Payaningal R Somanath
Journal:  J Cell Physiol       Date:  2018-06-01       Impact factor: 6.384

6.  Dietary flavonoid apigenin inhibits endothelin-1-induced contraction of collagen gel.

Authors:  Jae-Bum Jun; Young-In Na; Tae-Hwan Kim; Dae-Hyun Yoo
Journal:  Rheumatol Int       Date:  2009-12-11       Impact factor: 2.631

Review 7.  The pathogenesis of systemic sclerosis revisited.

Authors:  Matthias Geyer; Ulf Müller-Ladner
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

8.  Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma.

Authors:  Minghua Wu; Denisa S Melichian; Eric Chang; Matthew Warner-Blankenship; Asish K Ghosh; John Varga
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

9.  Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90.

Authors:  Banafsheh Nazari; Lisa M Rice; Giuseppina Stifano; Alexander M S Barron; Yu Mei Wang; Tess Korndorf; Jungeun Lee; Jag Bhawan; Robert Lafyatis; Jeffrey L Browning
Journal:  Am J Pathol       Date:  2016-08-23       Impact factor: 4.307

Review 10.  New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.

Authors:  Neil Ahluwalia; Barry S Shea; Andrew M Tager
Journal:  Am J Respir Crit Care Med       Date:  2014-10-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.